Targeting lymphocyte activation to treat rheumatoid arthritis - 21/07/09
páginas | 6 |
Iconografías | 1 |
Vídeos | 0 |
Otros | 0 |
Abstract |
The introduction of targeted treatments has radically changed the management of patients with rheumatoid arthritis (RA). Abatacept is among these new treatments emerging from recent insights into joint immunopathology. Abatacept blocks the interaction between antigen-presenting cells and T-cells, thereby diminishing T-cell activation and possibly improving overall cell regulation. In RA patients, abatacept is effective in decreasing the arthritis, pain, disability, fatigue, and radiological joint damage. Abatacept provides lasting remissions or low levels of disease activity and therefore constitutes a valuable addition to the current therapeutic armamentarium for RA, which is hoped to make a full remission an attainable goal in the overall population of RA patients.
El texto completo de este artículo está disponible en PDF.Keywords : Rheumatoid arthritis, T-cell/antigen-presenting cell interactions, Abatacept
Esquema
Vol 76 - N° 4
P. 327-332 - juillet 2009 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?